Total Payments
$367,934
2024 Payments
$16,270
Companies
16
Transactions
525
Medicare Patients
267
Medicare Billing
$30,417
Payment Breakdown by Category
Consulting$143,879 (39.1%)
Travel$72,103 (19.6%)
Other$59,225 (16.1%)
Education$47,811 (13.0%)
Research$36,849 (10.0%)
Food & Beverage$8,067 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $143,879 | 47 | 39.1% |
| Travel and Lodging | $72,103 | 75 | 19.6% |
| Education | $47,811 | 128 | 13.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,041 | 74 | 10.3% |
| Unspecified | $36,849 | 92 | 10.0% |
| Honoraria | $21,184 | 7 | 5.8% |
| Food and Beverage | $8,067 | 102 | 2.2% |
Payments by Type
General
$331,084
433 transactions
Research
$36,849
92 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $74,793 | 109 | $0 (2023) |
| F. Hoffmann-La Roche AG | $67,604 | 117 | $0 (2024) |
| Sarepta Therapeutics, Inc. | $65,094 | 51 | $0 (2024) |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $63,987 | 92 | $0 (2024) |
| AveXis | $33,412 | 80 | $0 (2019) |
| Genentech USA, Inc. | $19,012 | 16 | $0 (2024) |
| GENZYME CORPORATION | $9,639 | 24 | $0 (2023) |
| Vertex Pharmaceuticals Incorporated | $7,875 | 3 | $0 (2023) |
| Genentech, Inc. | $7,812 | 8 | $0 (2023) |
| Insmed, Inc. | $6,442 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,270 | 10 | Sarepta Therapeutics, Inc. ($5,320) |
| 2023 | $67,024 | 63 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) ($20,695) |
| 2022 | $60,078 | 48 | Sarepta Therapeutics, Inc. ($25,849) |
| 2021 | $27,269 | 41 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) ($14,544) |
| 2020 | $62,018 | 104 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) ($23,810) |
| 2019 | $74,961 | 142 | AveXis ($33,412) |
| 2018 | $34,028 | 75 | Biogen, Inc. ($8,592) |
| 2017 | $26,287 | 42 | Biogen, Inc. ($24,594) |
All Payment Transactions
525 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $306.87 | Research |
| Study: A Gene Delivery Study to Evaluate the Safety of and Expression From SRP-9001 in Duchenne Muscular Dystrophy (DMD) (ENDEAVOR) | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| 12/13/2024 | Genentech USA, Inc. | Evrysdi (Drug) | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| Category: Neurology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 08/22/2024 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,320.00 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $714.66 | Research |
| Study: RO7034067 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | ||||||
| 04/22/2024 | Novartis Pharmaceuticals Corporation | ZOLGENSMA (Drug) | Food and Beverage | In-kind items and services | $91.60 | General |
| Category: Neurology | ||||||
| 04/12/2024 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | ZOLGENSMA (Drug) | — | Cash or cash equivalent | $962.50 | Research |
| Study: Research Medical Writing and Publication Support • Category: Neurology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $274.10 | Research |
| Study: RO7034067 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | ||||||
| 02/09/2024 | Roche Products Limited | Evrysdi (Drug) | Consulting Fee | Cash or cash equivalent | $830.00 | General |
| Category: Neurology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,597.65 | Research |
| Study: Study of RG7916 in pre symptomatic SMA patients | ||||||
| 12/07/2023 | Genentech, Inc. | Evrysdi (Drug) | Food and Beverage | In-kind items and services | $140.68 | General |
| Category: Neurology | ||||||
| 12/01/2023 | F. Hoffmann-La Roche AG | — | Travel and Lodging | In-kind items and services | $10,863.05 | General |
| 12/01/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $5,040.00 | General |
| 12/01/2023 | F. Hoffmann-La Roche AG | — | Travel and Lodging | In-kind items and services | $737.06 | General |
| 12/01/2023 | F. Hoffmann-La Roche AG | — | Travel and Lodging | In-kind items and services | $347.25 | General |
| 12/01/2023 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $137.80 | General |
| 10/20/2023 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) | ZOLGENSMA (Biological) | Honoraria | Cash or cash equivalent | $4,128.00 | General |
| Category: GENE THERAPY | ||||||
| 10/06/2023 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 10/04/2023 | Sarepta Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $135.29 | General |
| 10/04/2023 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $91.60 | General |
| 10/04/2023 | Novartis Gene Therapies, Inc. (fka AveXis, Inc.) | ZOLGENSMA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $75.00 | General |
| Category: GENE THERAPY | ||||||
| 10/02/2023 | Sarepta Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 10/02/2023 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $401.28 | General |
| 10/02/2023 | Sarepta Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $175.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG | $10,392 | 13 |
| A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS. | F. Hoffmann-La Roche AG | $5,853 | 19 |
| A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease | GENZYME CORPORATION | $4,717 | 12 |
| Study of RG7916 in pre symptomatic SMA patients | F. Hoffmann-La Roche AG | $2,749 | 4 |
| A phase 4, open label, prospective study in patients with Pompe disease to evaluate the efficacy and safety of alglucosidase alfa produced at the 4000L scale | GENZYME CORPORATION | $1,876 | 3 |
| AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICSPHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG | $1,873 | 7 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis | Biogen, Inc. | $1,811 | 11 |
| AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICSPHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY, A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS., A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, IN | F. Hoffmann-La Roche AG | $1,539 | 6 |
| AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICSPHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY, A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS., A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILIT | F. Hoffmann-La Roche AG | $1,292 | 3 |
| RO7034067 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG | $988.76 | 2 |
| Research Medical Writing and Publication Support | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $962.50 | 1 |
| A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment naive patients with late onset Pompe disease | GENZYME CORPORATION | $750.00 | 2 |
| Systemic Gene Delivery Clinical Trial for Duchenne Muscular Dystrophy (DMD) | F. Hoffmann-La Roche AG | $385.47 | 2 |
| SAFETY UPDATE: RISDIPLAM CLINICAL TRIAL PROGRAM FOR SMA | F. Hoffmann-La Roche AG | $354.29 | 1 |
| A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) and alglucosidase alfa in treatment-nave | GENZYME CORPORATION | $340.00 | 2 |
| A Gene Delivery Study to Evaluate the Safety of and Expression From SRP-9001 in Duchenne Muscular Dystrophy (DMD) (ENDEAVOR) | F. Hoffmann-La Roche AG | $306.87 | 1 |
| RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS | F. Hoffmann-La Roche AG | $303.11 | 1 |
| STUDY OF RG7916 IN PRE SYMPTOMATIC SMA PATIENTS, AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICSPHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY, A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 AND 3 SPINAL MUSCULAR ATROPHY PATIENTS., A TWO PART SEAMLESS, OPEN-LABEL, MULTICE | F. Hoffmann-La Roche AG | $220.08 | 1 |
| Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Biogen, Inc. | $135.97 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 42 | 48 | $17,454 | $3,700 |
| 2022 | 2 | 64 | 84 | $29,221 | $6,540 |
| 2021 | 2 | 105 | 162 | $61,962 | $12,864 |
| 2020 | 1 | 56 | 76 | $28,706 | $7,313 |
Total Patients
267
Total Services
370
Medicare Billing
$30,417
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 26 | 28 | $12,234 | $3,234 | 26.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 16 | 20 | $5,220 | $465.99 | 8.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 41 | 53 | $21,130 | $5,803 | 27.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 23 | 31 | $8,091 | $737.01 | 9.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 62 | 84 | $41,604 | $10,707 | 25.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 43 | 78 | $20,358 | $2,157 | 10.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 56 | 76 | $28,706 | $7,313 | 25.5% |
About Dr. John Day, MD
Dr. John Day, MD is a Neurology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447291992.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Day, MD has received a total of $367,934 in payments from pharmaceutical and medical device companies, with $16,270 received in 2024. These payments were reported across 525 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($143,879).
As a Medicare-enrolled provider, Day has provided services to 267 Medicare beneficiaries, totaling 370 services with total Medicare billing of $30,417. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neuromuscular Medicine
- Location Stanford, CA
- Active Since 06/08/2006
- Last Updated 11/09/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1447291992
Products in Payments
- ZOLGENSMA (Biological) $84,847
- SPINRAZA (Biological) $52,568
- Non-Covered Product (Drug) $47,529
- Evrysdi (Drug) $18,164
- Exondys 51 (Drug) $15,894
- EXONDYS 51 (Drug) $7,410
- NEXVIAZYME (Biological) $2,500
- OCREVUS (Biological) $1,873
- LUMIZYME (Drug) $1,855
- LUMIZYME (Biological) $1,831
- MYOZYME (Drug) $1,372
- VILTEPSO (Drug) $1,326
- Emflaza (Drug) $1,269
- ZOLGENSMA (Drug) $1,054
- POMPE - DISEASE (Drug) $81.84
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Stanford
Gregory Albers, Md, MD
Neurology — Payments: $500,221
Neurology $500,221
Robert Cowan, Md, MD
Neurology — Payments: $253,351
Neurology $253,351
Josef Parvizi, Md, Phd, MD, PHD
Neurology — Payments: $215,697
Neurology $215,697
Chitra Venkatasubramanian, Md, MD
Neurology — Payments: $206,735
Neurology $206,735
Babak Razavi, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $121,290
Neurology $121,290
Kimford Meador, Md, MD
Neurology — Payments: $72,646
Neurology $72,646